bimekizumab   Click here for help

GtoPdb Ligand ID: 9411

Synonyms: Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Approved drug Immunopharmacology Ligand
bimekizumab is an approved drug (EMA (2021))
Compound class: Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].
Classification Click here for help
Compound class Antibody
Approved drug? Yes (EMA (2021))
International Nonproprietary Names Click here for help
INN number INN
9878 bimekizumab
Synonyms Click here for help
Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 486
Other databases
GtoPdb PubChem SID 328083513
Search PubMed clinical trials bimekizumab
Search PubMed titles bimekizumab
Search PubMed titles/abstracts bimekizumab